UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11846

2023

Volltextzugriff (PDF)

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses

International journal of molecular sciences, 2021-08, Vol.22 (16), p.9074

2021

Volltextzugriff (PDF)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231166779-20406207231166779

2023

Volltextzugriff (PDF)

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature

TH open : companion journal to thrombosis and haemostasis, 2021-04, Vol.5 (2), p.e183-e187

2021

Volltextzugriff (PDF)

Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis

Blood, 2023-11, Vol.142 (Supplement 1), p.5535-5535

2023

Volltextzugriff (PDF)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-05, Vol.26 (3), p.e145-e147

2020

Volltextzugriff (PDF)

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Blood, 2018-11, Vol.132 (Supplement 1), p.1189-1189

2018

Volltextzugriff (PDF)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-07, Vol.26 (4), p.e201-e204

2020

Volltextzugriff (PDF)

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Blood, 2018-11, Vol.132 (Supplement 1), p.1206-1206

2018

Volltextzugriff (PDF)

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Blood, 2019-11, Vol.134 (Supplement_1), p.1129-1129

2019

Volltextzugriff (PDF)

The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.20-20

2020

Volltextzugriff (PDF)

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Thrombosis research, 2019-11, Vol.183, p.13-19

2019

Volltextzugriff (PDF)

The potential role of emicizumab prophylaxis in severe von Willebrand disease

Blood cells, molecules, & diseases, 2021-03, Vol.87, p.102530-102530, Article 102530

2021

Volltextzugriff (PDF)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.e347-e356

2021

Volltextzugriff (PDF)

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e559-e562

2021

Volltextzugriff (PDF)

Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study

Blood, 2016-12, Vol.128 (22), p.4984-4984

2016

Volltextzugriff (PDF)

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

Advances in therapy, 2020-06, Vol.37 (6), p.2763-2776

2020

Volltextzugriff (PDF)

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.1011-1019

2019

Volltextzugriff (PDF)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

European journal of haematology, 2020-06, Vol.104 (6), p.594-601

2020

Volltextzugriff (PDF)

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Drugs in R&D, 2024-08

2024

Volltextzugriff (PDF)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study

Therapeutic advances in hematology, 2023-04, Vol.14

2023

Volltextzugriff (PDF)

BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Haemophilia : the official journal of the World Federation of Hemophilia, 2019

2019

Volltextzugriff (PDF)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center

Research and practice in thrombosis and haemostasis, 2023-08, Vol.7 (6), p.102178-102178, Article 102178

2023

Volltextzugriff (PDF)

Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon

The Israel Medical Association journal, 2017-02, Vol.19 (2), p.128-130

2017

Volltextzugriff (PDF)

Neonatal circumcision in patients with haemophilia is safe – a single centre experience

Journal of Haemophilia Practice, 2018-03, Vol.4 (1), p.32-34

2018

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(29)
Norwegisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature

Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

The potential role of emicizumab prophylaxis in severe von Willebrand disease

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study

BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center

Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon

Neonatal circumcision in patients with haemophilia is safe – a single centre experience

Suchergebnisse filtern